

3rd Childhood Diabetes Prevention Symposium

General Population Screening for T1D: CURRENT ISSUES in time of COVID-19

NOVEMBER 13,2020 / A VIRTUAL (ZOOM) EVENT

THE OBJECTIVES OF THIS SYMPOSIUM ARE TO:



Summarize current screening efforts worldwide




Discuss lessons learned from adjustments made for COVID-19 pandemic



Prioritize goals for the next 3 years

- Type 1 diabetes (T1D) affects 1.4 million people in the U.S.
- Clinical diagnosis is preceded by months or years of pre-symptomatic autoimmunity damaging insulin-producing cells in the pancreas. It can be detected through inexpensive screening for islet autoantibodies.
- The JDRF, the ADA, and the Endocrine Society have recognized that T1D should be diagnosed when a child develops multiple islet autoantibodies (stage 1), irreversibly progressing to dysglycemia (stage 2), and clinical diabetes (stage 3T1D).
- Early detection of stage 1T1D through screening is important because parents and providers often overlook symptoms of diabetes.
- As the result, 50% of children newly diagnosed with T1D in the U.S. present with lifethreatening diabetic ketoacidosis (DKA). They are at high risk of brain swelling, permanent memory deficits, and poor long-term diabetes control due to additional loss of insulin-producing cells during DKA.
- Screening for autoantibodies can reduce the risk of DKA to less than 5% and is cost-effective with a lifetime horizon.
- In addition, children identified through the screening as high-risk can participate in clinical trials to delay or prevent clinical diabetes.



The Barbara Davis Center for Diabetes (BDC)

specializes in Type 1 Diabetes (T1D) research and care for children and adults. It is one of the largest diabetes institutes in the world. The Center is part of the University of Colorado School of Medicine and has its dedicated building on the Anschutz Medical Campus in Aurora, Colorado.

The Center was funded by Marvin and Barbara Davis, in 1978, and is generously supported by the Children's Diabetes Foundation (CDF).

Clinicians, clinical researchers, and basic biomedical scientists work at the BDC to find the most effective treatment, prevention, and cure for T1D. The Center provides state-of-the-art diabetes care to 4,200 children and 2,800 adults with diabetes from the Rocky Mountain Region as well as receiving national and international referrals. We also provide inpatient care to patients who are seen at the Children's Hospital Colorado with any type of diabetes.

www.barbaradaviscenter.org

eneral Population Screening for RRENT ISSUES in time of CO

NOVEMBER 13,2020 / A VIRTUAL (ZOOM) EVENT

* All times EST

WELCOME & INTRODUCTION 10:00am

Marian Rewers MD. PhD

Barbara Davis Center for Diabetes

JDRF PERSPECTIVE 10:05am

Frank Martin PhD

JDRF Research Cure/Prevention

10:10am HELMSLEY TRUST PERSPECTIVE

Anne Koralova PhD

Helmsley Charitable Trust T1D Program

PUBLIC PRIVATE PARTNERSHIP INITIATIVE 10:15am

Jessica Dunne PhD

Janssen Research and Development

UPDATE FROM FR1DOLIN 10:30 am

> Olga Kordonouri MD, PhD Hannover Children's Hospital

UPDATE FROM PRIMED 10:40 am

Stephen Rich PhD

Center for Public Health Genomics, UVA

UPDATE FROM ASK 10:50 am

> Marian Rewers MD. PhD Barbara Davis Center for Diabetes

OPTIMAL AGE TO SCREEN/RESCREEN 11:00am

William Hagopian MD, PhD

Pacific Northwest Diabetes Research Institute

T1D1 SCREENING TOOLBOX 11:10am

Mohamed Ghalwash PhD

Center for Computational Health, IBM Research

THE SANFORD PROJECT 11:15am

Kurt Griffin MD, PhD & Nancy Konopasek BSRT

Sanford Health

AUSTRALIAN T1D SCREENING PROJECT 11:25am

> Kirstine Bell PhD Sydney University

ISRAELI T1D SCREENING PROJECT 11:30 am

Tal Oron MD

Schneider Children's Medical Center of Israel

PUBLIC HEALTH SARS-COV-2 ANTIBODY SCREENING 11:35 am

Markus Hippich MD

Helmholz Institute, Munich

Q&A 11:40 am

ADJOURN 12:00 Pm

